CARSON CITY — Nevada Attorney General Catherine Cortez Masto on Monday joined 44 other states and the District of Columbia in announcing a $100 million settlement with Abbott Laboratories over allegations of illegal off-label marketing of its Depakote drug.
As part of this settlement, Nevada will receive nearly $1.4 million to benefit consumer protection efforts. As a result of the state’s investigation, the Illinois-based Abbott will be restricted from marketing the drug for off-label uses not approved by the U.S. Food and Drug Administration, and has agreed to significantly change how it markets Depakote.
“Pharmaceutical companies must promote and market drug appropriately,” Masto said. “This settlement was reached because I felt Nevada consumers had not been adequately protected.”
The agreement marks the largest consumer protection-based pharmaceutical settlement ever reached.
In a complaint filed Monday along with the settlement agreement, the states alleged Abbott engaged in unfair and deceptive practices when it marketed Depakote for off-label uses. Depakote is approved for treatment of seizure disorders, mania associated with bipolar disorder and prophylaxis of migraines, but the attorneys general alleged Abbott marketed the drug for treating unapproved uses, including schizophrenia, agitated dementia and autism.